GLTO

#11856
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
28.69
28.69
Годовой диапазон
2.01
38.33
Дневное изменение
-0.76%
Месячное изменение
-6.00%
6-месячное изменение
+917.38%
Годовое изменение
+613.68%
Предыдущее закрытие
28.91
Открыть
28.69
Bid
Ask
Минимум
28.69
High
28.69
Объем
10
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 1.59 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-5.78
Коэффициент цена/денежный поток
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Новости